Beta Amyloid Peptide: Jobs: Postdoctoral Research Fellow

Employer

Brigham and Women's Hospital

Location

Boston, Massachusetts

Principal Investigator

Cynthia Lemere

Contact

For consideration for this position, please send a cover letter explaining your background and motivation, detailing how you feel your skills can enrich the group's activities and whether you require sponsorship now or in the future to work in the United States, contact information for three (3) references and a full CV including contact details as a combined PDF to:

Cynthia Lemere, Ph.D.

Associate Professor of Neurology, Harvard Medical School

60 Fenwood Road

Boston, MA 02115

Email: clemere@bwh.harvard.edu

Description

A postdoctoral fellow position is available immediately in the Lemere laboratory at Brigham and Women's Hospital to utilize a novel antibody to prevent amyloidosis, inflammation, and synaptic dysfunction in Alzheimer's disease. This position is funded by an NIH RF1/R01 research grant titled "AD Immunotherapy with a Novel CDC-Mutant Anti-Pyroglutamate-3 Abeta Antibody to Avoid Vascular Side Effects" under the direction of Dr. Cynthia Lemere. The department will appoint the successful candidate to the BWH Medical Staff as a research fellow and will propose that him or her for appointment as a research fellow at the Harvard Medical School (HMS); however, final approval of this appointment rests with HMS.

The Lemere Lab has made seminal discoveries regarding active and passive anti-amyloid immunization in amyloid mouse models over the past 20 years. These findings led to the establishment of an international collaborative effort between Dr. Lemere's lab and Vivoryon Therapeutics (formerly known as Probiodrug AG) in Germany). The NIH-funded project involves in vivo immunization studies in mice including MRI brain analysis, microPET imaging, behavioral testing, and microglia single cell genomics, as well as in vitro examination of the neuroprotective effects of the antibody. The laboratory is funded by multiple NIH and NASA grants to support research studies related to testing of therapeutic treatments, understanding the role of complement in neurodegenerative diseases, and estimating the CNS and cardiovascular risks of deep space radiation. The ultimate goal of the laboratory is to discover novel therapies that are relevant to Alzheimer's disease, neurodegeneration, and radiation-induced injury.

For more information about the Lemere Lab, please visit https://www.brighamandwomens.org/research/labs-and-projects/lemere/overview.

Requirements

The lab is looking for a candidate with a strong background in mouse studies, molecular biology techniques, tissue culture, and assays to quantify gene/protein expression. Experience with mouse behavior is desirable.

Prioritized candidates should demonstrate excellent scientific productivity, evidenced by high-quality publications, and be highly motivated to conduct independent research. Additionally, candidates should display good communication and interpersonal skills. M.D., Ph.D., or equivalent is required.

This article originally appeared in the "    https://www.alzforum.org/jobs/postdoctoral-research-fellow-1  " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice. 

Beta Amyloid Peptide: CONFERENCE COVERAGE: Society for Neuroscience Annual Meeting 2019

Organized around 10 major themes, this year's annual meeting attracted almost 23,000 scientists. Sessions in the Neurodegenerative Disorders and Injury theme drew the largest crowd, featuring more than 2,700 of SfN's total 14,000-plus presentations. Aβ, tau, and other protein pathologies dominated, but there was a renewed emphasis on gene therapy for neurological disorders. Tom Fagan brings you some highlights.  

This article originally appeared in the " https://www.alzforum.org/news/conference-coverage/society-neuroscience-annual-meeting-2019  " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice. 

Beta Amyloid Peptide: CONFERENCE CALENDAR: Proteostasis Consortium Seminars: Molecular Strategies for Proteostasis Maintenance by Ribosome-Associated Chaperones

Organizers: The Proteostasis Consortium led by Richard Morimoto, Ph.D., Northwestern University
Speaker: Elke Deuerling, PhD, Universität Konstanz
Meeting time: 12 PM EDT
Zoom link: https://stanford.zoom.us/j/94026057431  

This article originally appeared in the "   https://www.alzforum.org/conference-calendar/1355321  " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice. 

Beta Amyloid Peptide: Research Paper: Role of alpha-synuclein phosphorylation at Serine 129 in methamphetamine-induced neurotoxicity in vitro and in vivo

Abstract

The phosphorylation and aggregation of alpha-synuclein (α-Syn) play a key role in methamphetamine (METH)-induced dopaminergic neurotoxicity. The exact mechanism underlying the interaction between METH-induced neurotoxicity and α-Syn was poorly clarified. We aimed to figure out the role of serine 129 phosphorylation (pS129) of α-Syn on its aggregation and neurotoxicity in vitro and in vivo. In this study, we examined pS129 α-Syn expression in vitro and in vivo at the protein phosphorylation and genetic levels and evaluated its effect on METH-induced neurotoxicity. Here, we found that pS129 α-Syn was significantly increased after METH treatment; moreover, the neuronal α-Syn aggregation and apoptosis caused by METH exposure were significantly attenuated after inhibiting α-Syn phosphorylation. We demonstrate that pS129 α-Syn contributes to the aggregation of α-Syn, and that phosphorylated and aggregated forms of α-Syn play an important role in METH-induced neurotoxicity in dopaminergic neurons and SH-SY5Y cells, supporting a potential insight into the treatment of METH-induced neurotoxicity

This article originally appeared in the "    https://pubmed.ncbi.nlm.nih.gov/32568772/ " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice. 

Beta Amyloid Peptide: Grant:Ruth L. Kirschstein National Research Service Award (NRSA) Individual Fellowship for Students at Institutions with NIH-Funded Institutional Predoctoral Dual-Degree Training Programs (Parent F30)

This Funding Opportunity Announcement (FOA) will support students at institutions with NIH-funded institutional predoctoral dual-degree training programs. The purpose of the Kirschstein-NRSA, dual-doctoral degree, predoctoral fellowship (F30) is to enhance the integrated research and clinical training of promising predoctoral students, who are matriculated in a combined MD/PhD or other dual-doctoral degree training program (e.g. DO/PhD, DDS/PhD, AuD/PhD, DVM/PhD), and who intend careers as physician/clinician-scientists. Candidates must propose an integrated research and clinical training plan and a dissertation research project in scientific health-related fields relevant to the missions of the participating NIH Institutes and Centers. The fellowship experience is expected to clearly enhance the individual's potential to develop into a productive, independent physician/clinician-scientist.

This Funding Opportunity Announcement (FOA) is designed specifically for candidates proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial, but does allow candidates to propose research experience in a clinical trial led by a sponsor or co-sponsor.

Standard dates apply, by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Standard AIDS dates apply, by 5:00 PM local time of applicant organization. All types of AIDS and AIDS-related applications allowed for this funding opportunity announcement are due on these dates.

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Required Application Instructions

It is critical that applicants follow the Fellowship (F) instructions in the SF424 (R&R) Application Guide except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance to all requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

1. Use the NIH ASSIST system to prepare, submit and track your application online.
   
   

This article originally appeared in the "   https://grants.nih.gov/grants/guide/pa-files/PA-20-248.html      " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice. 

Beta Amyloid Peptide: JOBS:

Postdoctoral Scientist

Posted 09 Jul 2020

Employer

Columbia University Irving Medical Center

Location

New York, New York

Principal Investigator

Abid Hussaini

Contact

sah2149@columbia.edu

Description

The Taub Institute for Research on Alzheimer's disease and the Aging Brain is seeking a Postdoctoral Scientist to join the laboratory of Dr. Abid Hussaini. The lab is focused on understanding the neurobiological underpinnings of Alzheimer's disease. Research involves studying the neuronal population in the brain that are affected by amyloid beta (Aβ) and tau pathology leading to cognitive deficits. We utilize several lines of transgenic mouse models of Alzheimer's disease to achieve our aims and routinely employ in vivo electrophysiology, behavioral testing and chemogenetics in our research. The lab is newly funded with NIH and foundation (including Alzheimer's association) grants and the position will be supported for up to 4 years.  The qualified candidate will be self-motivated, organized and able to work both independently and as part of a research team. Successful candidate will work on an independent project developing tools for in vivo electrophysiology/optogenetic experiments combined with virtual reality behavior testing in mice and analyzing large-scale extracellular single-unit, LFP and behavioral data. 

Responsibilities:

• Develop hardware tools for electrophysiology, optogenetic and behavior experiments.
• Analyze large-scale data pertaining to in vivo electrophysiology and behavior data.
• Develop and maintain MATLAB, Python and C++ software and code for experiments.
• Work with collaborators to incorporate machine learning algorithms into analysis.
• Present findings at meetings/conferences and publish in peer-reviewed journals.
• Train and supervise students/staff in handling hardware and software tools.

Requirements

Minimum Qualifications

• Ph.D. in neuroscience, physics, math, or other related fields.
• Excellent programming skills in MATLAB, Python and C# with experience in signal processing.
• Strong understanding of experimental design and statistical analysis e.g. R.
• Some engineering skills with experience in electronics, computer hardware and IoT.
• Excellent communication skills (writing and verbal) in English.

Optional Qualifications

• Experience with gaming engine and software such as Unity and Blender is highly desirable.
• Experience with machine learning is desirable.
• Experience handling rodents would be a plus.

This article originally appeared in the "  https://www.alzforum.org/jobs/postdoctoral-scientist-1    " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice. 

Beta Amyloid Peptide: JOBS: Postdoctoral Research Scholar, Edson Foundation

Employer

ASU-Banner Neurodegenerative Disease Research Center at Arizona State University

Location

Tempe, Arizona

Principal Investigator

Ben Readhead

Contact

Application Instructions: Applicants are responsible for including a cover letter, CV, and the names of three professional references in the application through the Interfolio website, https://apply.interfolio.com/72796. Emailed applications will not be accepted.

Applications will continue to be accepted on a rolling basis for a reserve pool.  Applications in the reserve pool may then be reviewed in the order in which they were received until the position is filled. They will continue on a biweekly basis until the position is filled.

Description

The Edson postdoctoral research scholar will have a primary mentor in the NDRC, but will have the opportunity to collaborate with other investigators. The selected candidate will work on projects utilizing highly dimensional genomic data, especially next-generation sequencing data for multilevel "omics" data analyses, with a focus on the identification of genes/drug targets implicated in neurodegenerative diseases, especially Alzheimer's disease. 

Essential Duties:

• Write and optimize computational pipelines (scripts) for whole genome/exome sequencing, RNA-seq, and/or microarray.
• Organize, prepare and analyze data; develop hypotheses to be tested and ways of testing it.
• Prepare and present the results of research, in scientific conferences and journals.
• Assist with grant preparation and reporting.
• A background check is required for employment. Arizona State University is a VEVRAA Federal Contractor and an Equal Opportunity/Affirmative Action Employer. All qualified applicants will be considered without regard to race, color, sex, religion, national origin, disability, protected veteran status, or any other basis protected by law.

(See https://www.asu.edu/aad/manuals/acd/acd401.html and https://www.asu.edu/titleIX/.)

In compliance with federal law, ASU prepares an annual report on campus security and fire safety programs and resources.  ASU's Annual Security and Fire Safety Report is available online at https://www.asu.edu/police/PDFs/ASU-Clery-Report.pdf  Applicants may request a hard copy of the report by contacting the ASU Police Department at 480-965-3456.

Requirements

Required Qualifications:

• Applicants must have a Ph.D. by May 31, 2020, in bioinformatics, genomics, computational biology, biostatistics, epidemiology, or related field to be considered.

Desired Qualifications:

• Experience with Linux/Unix-based systems, developing shell scripts/command-line interface, demonstrable experience in large-scale data analysis and utilization of high-performance computing systems.
• Formal training/experience in analyzing next-generation sequencing (NGS) or microarray data for gene expression, genotyping, or epigenetics.
• Experience with scientific computing and data-visualization tools and scripting languages such as Python/Perl/R/Matlab, and understanding of intermediate level of statistics.
• Excellent communication skills.
• Experience in genomic data analysis of neurodegenerative diseases is desired but not required.

This article originally appeared in the "  https://www.alzforum.org/jobs/postdoctoral-research-scholar-edson-foundation " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice. 

Beta Amyloid Peptide: JOBS: Director, Center for Brain Health & Associate Professor or Professor of IMSD

Employer

Florida Atlantic University

Location

Boca Raton, Florida

Contact

All applicants must apply electronically to the currently posted position (Director, Center for Brain Health & Associate Professor or Professor of Integrated Medical Science) on the Office of Human Resources' job website by completing the required online employment application and submitting the related documents. When completing the online application, please upload a cover letter, curriculum vitae, and copies of official transcripts scanned into an electronic format.

Any confidential letters of recommendation/references may be sent to Sara Greene, greenes@health.fau.edu.

A background check will be required for the candidate selected for this position. This position is subject to funding.

For more information and to apply, visit www.fau.edu/jobsand go to Apply Now (REQ08851).

Description

The Charles E. Schmidt College of Medicine, Florida Atlantic University (FAU), is seeking a world-class clinician scientist to develop an academically oriented program aimed at reducing the toll of Alzheimer's disease (AD) and related dementias in Florida and beyond. The ideal clinician scientist will be a national leader in deep phenotyping and deploying personalized approaches for the prevention, diagnosis, and treatment of the full spectrum of dementias.

Operating within an integrated health practice model, the clinician scientist will build and shape a comprehensive program in brain health, with possibilities for collaboration through partnerships with FAU centers and institutes, including the Louis and Anne Green Memory and Wellness Center, a dementia specific program providing supportive services to ~4,500 unique patients annually, and the Brain Institute, a university research pillar dedicated to the advancement of neuroscience research, education, and community outreach. Additional outstanding clinical and research partnerships are available through the Marcus Neuroscience Institute at Boca Raton Regional Hospital, Scripps Research Institute Florida, and the Max Planck Florida Institute for Neuroscience.

Florida Atlantic University is an equal opportunity/affirmative action/equal access institution and all qualified applicants will receive consideration without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability status, protected veterans status or other protected status. Individuals with disabilities requiring accommodation, please call 561-297-3057. 711.

FAU is committed to the principles of engaged teaching, research and service.  All persons aspiring to achieve excellence in the practice of these principles are encouraged to apply.

Requirements

Minimum Qualification:

Experience:

• Board-certified neurologist, psychiatrist or neuropsychologist with expertise in Alzheimer's disease, and/or Lewy body dementia, and other dementias
• Academic credentials from an accredited institution that merit appointment at associate or full professor in the College of Medicine by the time of application
• Distinguished record in clinical translational research, and education
• Proven record of broad, progressive and substantive administrative leadership
• Experience in clinical trials research
• Experience in building diverse and multi-disciplinary teams
• Innovative program development leadership from a start-up phase
• Strong track record in external funding and program or center leadership, with active foundation, state, and/or federal research grant funding, in the areas of Alzheimer's disease, Lewy body dementia, or other dementias

Knowledge/Skills:

• Knowledge of trends and issues in integrative health with respect to the prevention and treatment of dementias
• Ability to engage with community and establish effective partnerships in an academic environment
• Rigorous with data and metrics
• Outstanding communication skills
• Budgetary and financial management skills
• Ability to build and sustain effective teams, including inter-professional and interdisciplinary
• Management skills that include collegiality and respect
• Excellence in problem solving
• Outstanding communication skills, including effective communication in a culturally and ethnically diverse community

Characteristics:

• Commitment to diversity and inclusion as a means of achieving institutional excellence
• Ability to communicate effectively in a culturally and ethnically diverse community
• Emotional intelligence
• Divergent thinking
• Effective decision maker
• Collaborative
• Transparent
• Community-focused
• Entrepreneurial
• Commitment to excellence in clinical practice, teaching, research, and community engagement/service
• Capacity to advance strategic initiatives and achieve targeted goals
• Commitment to building and bridging partnership

This article originally appeared in the "  https://www.alzforum.org/jobs/director-center-brain-health-associate-professor-or-professor-imsd   " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice. 

Beta Amyloid Peptide: CONFERENCE COVERAGE: Clinical Trials on Alzheimer's Disease 2019

Following up on its October surprise, Biogen showed more data at the Clinical Trials in Alzheimer's Disease conference, arguing that disparities in drug exposure explained the puzzlingly different outcomes in its one positive and one negative aborted Phase 3 trials. Audience members were put off by the messiness of the data set and not fully convinced by the analysis, but the majority said they believed the general signal that the antibody may slow disease progression. The prevailing mood was one of hopefulness, with most agreeing the results validate the amyloid hypothesis and suggest that effective treatments for AD are within reach.  

This article originally appeared in the "  https://www.alzforum.org/news/conference-coverage/clinical-trials-alzheimers-disease-2019  " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice.  

Beta Amyloid Peptide: CONFERENCE COVERAGE: Human Amyloid Imaging 2020

PET imaging is adding a new layer of understanding to scientists' concept of Alzheimer's disease pathogenesis and progression. At the 14th Human Amyloid Imaging conference, speakers detailed nuances in the relationship between plaques, tangles, and cognitive decline. They also described nascent efforts to tie pathology in specific brain regions to specific behavioral and cognitive symptoms. While HAI featured new data on the pros and cons of various tau tracers in development, the synaptic tracer UCB-J jumped to the fore. It appears to detect synapse loss throughout AD cortex, as well as in other neurodegenerative diseases such as frontotemporal dementia and progressive supranuclear palsy.  

This article originally appeared in the "  https://www.alzforum.org/news/conference-coverage/human-amyloid-imaging-2020 " and has their copyrights. We do not claim copyright on the content. This information is for research purposes only. This Blog is made available by publishers for educational purposes only as well as to give you general information and a general understanding , not to provide specific advice. By using this blog site you understand that there is no client relationship between you and the Blog publisher. The Blog should not be used as a substitute for competent research advice.